Exosome Diagnostics grabs $60 mln Series B
Cambridge, Massachusetts-based Exosome Diagnostics Inc, a liquid biopsy platform developer, has raised $60 million in Series B funding. The investors included Forbion Capital Partners, NGN Capital, CD Ventures, Qiagen, Arcus Ventures, Tiger Management and Blue Ridge Capital.
8 January 2016•3 mins read
